Merck & Company Inc (MRK)vsSIGA Technologies Inc (SIGA)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
SIGA
SIGA Technologies Inc
$4.60
+1.55%
HEALTHCARE · Cap: $328.85M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 68640% more annual revenue ($65.01B vs $94.58M). MRK leads profitability with a 28.1% profit margin vs 24.6%. MRK appears more attractively valued with a PEG of 3.36. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
SIGA
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Margin of Safety
+77.1%
Fair Value
$29.05
Current Price
$4.60
$24.45 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Earnings expanding 1802.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 25 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Revenue declined 95.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : SIGA
The strongest argument for SIGA centers on EPS Growth, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 24.6% and operating margin at -250.4%.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : SIGA
The primary concerns for SIGA are Market Cap, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
MRK profiles as a value stock while SIGA is a declining play — different risk/reward profiles.
SIGA carries more volatility with a beta of 1.06 — expect wider price swings.
MRK is growing revenue faster at 5.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 54/100), backed by strong 28.1% margins. SIGA offers better value entry with a 77.1% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →SIGA Technologies Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health safety and infectious disease markets in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?